A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Varlitinib Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer as Second Line Systemic Therapy
Phase of Trial: Phase II/III
Latest Information Update: 31 Jan 2018
At a glance
- Drugs Varlitinib (Primary) ; Capecitabine
- Indications Biliary cancer; Biliary tract disorders
- Focus Adverse reactions; Therapeutic Use
- Acronyms TreeTopp
- Sponsors ASLAN Pharmaceuticals
- 31 Jan 2018 According to an ASLAN Pharmaceuticals media release, the design of this trial will be presented at the Cholangiocarcinoma Foundation Annual Conference 2018.
- 25 Oct 2017 Status changed from not yet recruiting to recruiting.
- 30 Mar 2017 New trial record